Lineage Cell Therapeutics (LCTX) Cash & Equivalents (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Cash & Equivalents of $45.3 million for Q1 2026, down 5.45% year-over-year from $47.9 million in Q1 2025, and down 1.5% quarter-over-quarter from $46.0 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Cash & Equivalents (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $45.3 million for Q1 2026.
- In Q1 2026, Cash & Equivalents fell 5.45% year-over-year to $45.3 million; the TTM figure through Mar 2026 stood at $45.3 million (down 5.45% YoY), while the FY2025 annual figure was $46.0 million, up 12.06% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $45.3 million, down from $46.0 million in the prior quarter.
- The five-year high for Cash & Equivalents was $78.1 million in Q1 2022, with the low at $11.4 million in Q4 2022.
- The 5-year median for Cash & Equivalents is $33.9 million (2023), against an average of $38.3 million.
- The sharpest annual moves came in 2023 and 2024: Cash & Equivalents tumbled 80.21% in 2023, then jumped 182.03% in 2024.
- Lineage Cell Therapeutics' Cash & Equivalents stood at $11.4 million in 2022, then surged by 163.63% to $29.9 million in 2023, then surged by 37.02% to $41.0 million in 2024, then climbed by 12.06% to $46.0 million in 2025, then declined by 1.5% to $45.3 million in 2026.
- Business Quant data shows LCTX's Cash & Equivalents at $45.3 million in Q1 2026, $46.0 million in Q4 2025, and $32.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 43.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.25 Mn |
| Mar 31, 2026 | 45.28 Mn |
| Dec 31, 2025 | 45.97 Mn |
| Sep 30, 2025 | 32.22 Mn |
| Jun 30, 2025 | 42.27 Mn |
| Mar 31, 2025 | 47.89 Mn |
| Dec 31, 2024 | 41.02 Mn |
| Sep 30, 2024 | 27.75 Mn |
| Jun 30, 2024 | 29.62 Mn |
| Mar 31, 2024 | 43.58 Mn |
| Dec 31, 2023 | 29.94 Mn |
| Sep 30, 2023 | 31.47 Mn |
| Jun 30, 2023 | 33.89 Mn |
| Mar 31, 2023 | 15.45 Mn |
| Dec 31, 2022 | 11.36 Mn |
| Sep 30, 2022 | 24.75 Mn |
| Jun 30, 2022 | 70.86 Mn |
| Mar 31, 2022 | 78.06 Mn |
| Dec 31, 2021 | 55.74 Mn |
| Sep 30, 2021 | 60.81 Mn |